Research
Hormonal
Tirzepatide (15 mg) demonstrates superior weight loss efficacy compared to semaglutide (1 mg) in patients with type 2 diabetes, achieving 13.1% weight loss versus 9.7 kg (9.6%) for semaglutide 2.4 mg in direct comparison trials.
For patients with type 2 diabetes needing significant weight loss, tirzepatide (15 mg weekly) has shown higher weight loss percentages (13.1%) compared to semaglutide (1 mg weekly) in head-to-head trials. This requires a slow 20-week titration to manage side effects, which may impact adherence.
StrongSupportsVERY_HIGH confidence
Injection of tirzepatide at 15 mg for the same duration lowered the body weight by 13.1% in SURPASS-2 with an ETD of 6.4% compared to semaglutide 1 mg treatment.
Why this rating
Based on SURPASS-2, a large phase III randomized trial.
Source
The Upcoming Weekly Tides (Semaglutide vs. Tirzepatide) against Obesity: STEP or SURPASS?
Han Na Jung et al. · Journal of Obesity & Metabolic Syndrome · 2022
DOI 10.7570/jomes22012
narrative_review · n=3567Cited 31×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →